Background: Programmed cell death protein 4(PDCD4) is a novel tumor suppressor protein involved in pro?grammed cell death. Its association with cancer progression has been observed in multiple tumor models, but eviden...Background: Programmed cell death protein 4(PDCD4) is a novel tumor suppressor protein involved in pro?grammed cell death. Its association with cancer progression has been observed in multiple tumor models, but evidence supporting its association with solid tumors in humans remains controversial. This study aimed to determine the clinical signiicance and prognostic value of PDCD4 in solid tumors.Methods: A systematic literature review was performed to retrieve publications with available clinical informa?tion and survival data. The eligibility of the selected articles was based on the criteria of the Dutch Cochrane Centre proposed by the Meta?analysis Of Observational Studies in Epidemiology group. Pooled odds ratios(ORs), hazard ratios(HRs), and 95% conidence intervals(CIs) for survival analysis were calculated. Publication bias was examined by Begg's and Egger's tests.Results: Clinical data of 2227 cancer patients with solid tumors from 23 studies were evaluated. PDCD4 expression was signiicantly associated with the diferentiation status of head and neck cancer(OR 4.25, 95% CI 1.87–9.66) and digestive system cancer(OR 2.87, 95% CI 1.84–4.48). Down?regulation of PDCD4 was signiicantly associated with short overall survival of patients with head and neck(HR: 3.44, 95% CI 2.38–4.98), breast(HR: 1.86, 95% CI 1.36–2.54), digestive system(HR: 2.12, 95% CI 1.75–2.56), and urinary system cancers(HR: 3.16, 95% CI 1.06–9.41).Conclusions: The current evidence suggests that PDCD4 down?regulation is involved in the progression of several types of solid tumor and is a potential marker for solid tumor prognoses. Its clinical usefulness should be conirmed by large?scale prospective studies.展开更多
目的探讨miR-21在肾透明细胞癌中的表达及其临床意义,以及如何通过调节程序性细胞死亡因子4(programmed cell death 4,PDCD4)的表达影响786-O肾透明细胞癌细胞系的增殖和凋亡。方法通过分析The Cancer Genome Atlas(TCGA)肾透明细胞癌...目的探讨miR-21在肾透明细胞癌中的表达及其临床意义,以及如何通过调节程序性细胞死亡因子4(programmed cell death 4,PDCD4)的表达影响786-O肾透明细胞癌细胞系的增殖和凋亡。方法通过分析The Cancer Genome Atlas(TCGA)肾透明细胞癌数据库,比较癌组织及正常癌旁组织中miR-21的表达水平;分析miR-21表达水平在不同临床病理分期肾癌组织中的差异;采用Kaplan-Meier法和对数秩和检验(Log-rank test)研究miR-21表达水平和患者生存之间的关系;通过转染miR-21抑制性核苷酸(AS-miR-21)下调miR-21表达水平,采用MTT和流式细胞术分别检测细胞增殖和凋亡,采用实时定量PCR(qRT-PCR)和Western blot测量PDCD4mRNA和蛋白质表达水平变化,采用双荧光素报告系统检测miR-21对PDCD4的直接调节。结果肾透明细胞癌组织中miR-21的表达水平显著高于癌旁组织(P<0.000 1)。miR-21在Ⅲ期和Ⅳ期肾癌组织中表达水平显著高于Ⅰ期(P均<0.000 1),miR-21表达水平与临床病理分期呈正相关(r=0.262,P<0.000 1)。miR-21表达水平与T分期(r=0.250,P<0.000 1)与淋巴结转移阳性(N1)以及远处转移均呈正相关(P均<0.001)。生存分析显示miR-21高表达患者中位生存时间显著短于miR-21低表达者中位生存时间(Log-rank,P<0.001)。下调miR-21后,786-O细胞的增殖能力较对照显著降低(P<0.05),凋亡显著增加(P=0.005),PDCD4mRNA(P=0.002)和蛋白质表达水平显著增高。双荧光素报告实验显示在转染AS-miR-21的细胞内PDCD4相对荧光强度较对照细胞显著升高(P=0.003)。结论 miR-21在肾透明细胞癌组织中表达升高,与患者临床病理分期呈正相关,和患者生存呈负相关;miR-21可能通过调节PDCD4表达水平,参与调节肾透明细胞癌细胞的增殖和凋亡。展开更多
目的:研究远隔缺血预适应(RIPC)对脑缺血模型大鼠的保护作用及分子机制。方法:18只成年雄性SD大鼠随机分为3组:假手术组(sham)、缺血再灌注组(MCAO/R)组、RIPC+MCAO/R组;术前利用间断夹闭双侧股动脉的方法给予大鼠RIPC处理,利用大脑中...目的:研究远隔缺血预适应(RIPC)对脑缺血模型大鼠的保护作用及分子机制。方法:18只成年雄性SD大鼠随机分为3组:假手术组(sham)、缺血再灌注组(MCAO/R)组、RIPC+MCAO/R组;术前利用间断夹闭双侧股动脉的方法给予大鼠RIPC处理,利用大脑中动脉栓塞法(MCAO)制备大鼠缺血性脑卒中模型,利用转棒实验检测大鼠运动功能,利用TUNEL染色检测缺血区细胞凋亡,利用real time RT⁃PCR检测大脑缺血区皮质中miR⁃21⁃5p及SPRY1和程序性细胞死亡因子4(PDCD4)mRNA的表达。结果:与MCAO/R组大鼠相比,RIPC处理组大鼠运动功能有所改善,皮质细胞凋亡减少。miR⁃21⁃5p表达增加,而SPRY1和PDCD4 mRNA表达下调(P<0.05)。结论:RIPC处理对减轻缺血性脑卒中大鼠miR⁃21⁃5p表达上调,后者通过抑制靶分子SPRY1和PDCD4的表达抑制细胞凋亡。展开更多
文摘Background: Programmed cell death protein 4(PDCD4) is a novel tumor suppressor protein involved in pro?grammed cell death. Its association with cancer progression has been observed in multiple tumor models, but evidence supporting its association with solid tumors in humans remains controversial. This study aimed to determine the clinical signiicance and prognostic value of PDCD4 in solid tumors.Methods: A systematic literature review was performed to retrieve publications with available clinical informa?tion and survival data. The eligibility of the selected articles was based on the criteria of the Dutch Cochrane Centre proposed by the Meta?analysis Of Observational Studies in Epidemiology group. Pooled odds ratios(ORs), hazard ratios(HRs), and 95% conidence intervals(CIs) for survival analysis were calculated. Publication bias was examined by Begg's and Egger's tests.Results: Clinical data of 2227 cancer patients with solid tumors from 23 studies were evaluated. PDCD4 expression was signiicantly associated with the diferentiation status of head and neck cancer(OR 4.25, 95% CI 1.87–9.66) and digestive system cancer(OR 2.87, 95% CI 1.84–4.48). Down?regulation of PDCD4 was signiicantly associated with short overall survival of patients with head and neck(HR: 3.44, 95% CI 2.38–4.98), breast(HR: 1.86, 95% CI 1.36–2.54), digestive system(HR: 2.12, 95% CI 1.75–2.56), and urinary system cancers(HR: 3.16, 95% CI 1.06–9.41).Conclusions: The current evidence suggests that PDCD4 down?regulation is involved in the progression of several types of solid tumor and is a potential marker for solid tumor prognoses. Its clinical usefulness should be conirmed by large?scale prospective studies.
文摘目的:研究远隔缺血预适应(RIPC)对脑缺血模型大鼠的保护作用及分子机制。方法:18只成年雄性SD大鼠随机分为3组:假手术组(sham)、缺血再灌注组(MCAO/R)组、RIPC+MCAO/R组;术前利用间断夹闭双侧股动脉的方法给予大鼠RIPC处理,利用大脑中动脉栓塞法(MCAO)制备大鼠缺血性脑卒中模型,利用转棒实验检测大鼠运动功能,利用TUNEL染色检测缺血区细胞凋亡,利用real time RT⁃PCR检测大脑缺血区皮质中miR⁃21⁃5p及SPRY1和程序性细胞死亡因子4(PDCD4)mRNA的表达。结果:与MCAO/R组大鼠相比,RIPC处理组大鼠运动功能有所改善,皮质细胞凋亡减少。miR⁃21⁃5p表达增加,而SPRY1和PDCD4 mRNA表达下调(P<0.05)。结论:RIPC处理对减轻缺血性脑卒中大鼠miR⁃21⁃5p表达上调,后者通过抑制靶分子SPRY1和PDCD4的表达抑制细胞凋亡。
